Companies see a commercial opportunity in creating new ways to administer drugs to patients – in space.

Ren Jinsheng, founder and chairman of Simcere Pharmaceutical Group, said during an event held in April that China has unique ...

While rare disease research has advanced significantly, related expertise and data are scattered across too many disconnected places.

Cancer drug development has never moved faster. Yet, for too many patients, the next treatment decision still begins with ...

A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk ...

Daraxonrasib doubles survival — a RAS‑targeting drug development breakthrough.

The pharmaceutical industry invests heavily in technologies—$57.4 billion in 2022 alone—to discover new therapies to treat our greatest health challenges. Yet drug development teams are still using ...

Federal drug officials are aiming to significantly reduce the timeline for new drug development by launching real-time ...

In a rare move, nonprofit organization Blood Cancer United is buying the remaining supplies of a discontinued investigational ...

Pharma R&D is at a crossroads: the pressure to accelerate innovation, ensure compliance and manage fragmented data has never ...

Discover how quality-driven drug development and AI accelerate safer medicines, reduce risk, and improve patient outcomes.